Cite
HARVARD Citation
Hussain, M. et al. (n.d.). A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. European journal of cancer. 51 (13), pp. 1714-1724. [Online].